New s ‐Triazine–Hydrazone Hybrids Targeting EGFR: Design and Anticancer Activity Against A549 Lung Adenocarcinoma
Journal of Chemistry · 2026-01 · 2026 (1)
DOI: 10.1155/joch/4469525 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Chemistry, online erschienen am 01.03.2026. Verfasst von Hessa H. Al-Rasheed und 10 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Saud University.
Abstract (Originalsprache)
A new series of pyridine– s ‐triazine–hydrazone derivatives was designed, synthesized via an efficient two‐step route, and fully characterized by 1 H‐NMR, 13 C‐NMR, and elemental analyses. The compounds were evaluated for antiproliferative activity against A549 lung cancer cells and cytotoxicity toward WI‐38 fibroblasts. All derivatives showed measurable activity, with 6f and 6j exhibiting superior potency (IC 50 = 0.162 ± 0.01 and 0.152 ± 0.016 μm) compared with sorafenib (0.195 ± 0.02 μm), along with improved safety and selectivity indices. Both compounds also demonstrated strong antitrypsin activity, moderate Factor Xa inhibition, and enhanced EGF inhibitory effects relative to sorafenib. Molecular docking revealed binding scores of −6.856 to −4.812 and MM‐GBSA energies of −51.57 to −42.77 kcal/mol, exceeding those of sorafenib (docking score −4.805; ΔG‐bind = −35.02 kcal/mol). Docking analyses also indicated potential dual inhibition via interactions at the EGFR active site and MEK1 allosteric site, indicating stronger predicted EGFR binding affinities than sorafenib supporting a multitarget mechanism. Overall, 6f and 6j emerge as promising lead candidates for further development as dual EGFR/MEK inhibitors with additional protease‐modulating potential in NSCLC therapy.
Förderung
- King Saud University
Zitieren
APA
Al-Rasheed, H. H., Al-Khamis, S. A., Barakat, A., Masoud, A. A., Sobhy, A. A., Demellawy, M. E., Ghareeb, D. A., Sharma, A., Torre, B. G. D. L., Albericio, F., & El-Faham, A. (2026). New s ‐Triazine–Hydrazone Hybrids Targeting EGFR: Design and Anticancer Activity Against A549 Lung Adenocarcinoma. Journal of Chemistry, 2026(1). https://doi.org/10.1155/joch/4469525
Vancouver
Al-Rasheed HH, Al-Khamis SA, Barakat A, Masoud AA, Sobhy AA, Demellawy ME, et al. New s ‐Triazine–Hydrazone Hybrids Targeting EGFR: Design and Anticancer Activity Against A549 Lung Adenocarcinoma. Journal of Chemistry. 2026;2026(1). doi:10.1155/joch/4469525
BibTeX
@article{AlRasheed2026,
author = {Al-Rasheed, Hessa H. and Al-Khamis, Sarah A. and Barakat, Assem and Masoud, Aliaa A. and Sobhy, Ahmed A. and Demellawy, Maha El and Ghareeb, Doaa A. and Sharma, Anamika and Torre, Beatriz G. de la and Albericio, Fernando and El-Faham, Ayman},
title = {New s ‐Triazine–Hydrazone Hybrids Targeting EGFR: Design and Anticancer Activity Against A549 Lung Adenocarcinoma},
journal = {Journal of Chemistry},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/joch/4469525}
}
EUVIMED